• Profile
Close

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort

HIV Medicine Aug 01, 2021

Fabbiani M, Rossetti B, Ciccullo A, et al. - The efficacy and durability of treatment switching to two-drug (2DR) vs three-drug (3DR) integrase inhibitor (InSTI)-based regimens were investigated in a real-life setting. Within the ODOACRE cohort, researchers selected a total of 1,666 patients for inclusion. Of these patients, 1,334 (80%) received treatment with a 3DR regimen (19.9%, 25.0% and 55.1% elvitegravir-, raltegravir- and dolutegravir-based, respectively) and 332 (20%) with a 2DR (79.2% dolutegravir + lamivudine and 20.8% dolutegravir + rilpivirine) regimen. Per outcomes, 2DRs show an efficacy similar to 3DRs in virologically suppressed HIV-infected patients but with better tolerability.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay